Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152272 | 0.84 | CYP2C19 (0.42) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL19841974 | 0.83 | OPRM1 (0.38) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL7928918 | 0.82 | CYP2C19 (0.39) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL16925440 | 0.82 | OPRM1 (0.41) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL20390051 | 0.82 | OPRM1 (0.47) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL2728151 | 0.81 | ALDH1A1 (0.38) | OPRM1CYP3A4CYP2C19 | |
| SCHEMBL19842011 | 0.81 | OPRM1 (0.40) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1971303 | 0.78 | OPRM1 (0.38) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL18088169 | 0.75 | TMEM97 (0.48) | CYP2C19 | |
| SCHEMBL12049755 | 0.74 | OPRM1 (0.53) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-9884831-B2 | Azocane and azonane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201590-A1 | AZOCANE AND AZONANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, SLC10A1 | OPRM1 4802/4885OPRD1 4843/4885OPRK1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.